17.52 USD
+0.02 (+0.11%)
At close: Feb 3, 2026
17.52 USD
0 (0%)
After Hours: 2/3/2026, 8:00:00 PM
ADMA gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make ADMA suitable for growth investing!
1. Profitability
1.1 Basic Checks
- In the past year ADMA was profitable.
- In the past year ADMA had a positive cash flow from operations.
- ADMA had negative earnings in 4 of the past 5 years.
- In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
- The Return On Assets of ADMA (36.83%) is better than 98.86% of its industry peers.
- ADMA's Return On Equity of 48.57% is amongst the best of the industry. ADMA outperforms 98.66% of its industry peers.
- ADMA has a Return On Invested Capital of 25.76%. This is amongst the best in the industry. ADMA outperforms 98.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of ADMA (42.87%) is better than 98.09% of its industry peers.
- With an excellent Operating Margin value of 34.19%, ADMA belongs to the best of the industry, outperforming 97.52% of the companies in the same industry.
- With a decent Gross Margin value of 54.71%, ADMA is doing good in the industry, outperforming 76.72% of the companies in the same industry.
- ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
- ADMA has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, ADMA has more shares outstanding
- ADMA has a better debt/assets ratio than last year.
2.2 Solvency
- ADMA has an Altman-Z score of 20.23. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 20.23, ADMA belongs to the best of the industry, outperforming 89.12% of the companies in the same industry.
- ADMA has a debt to FCF ratio of 1.78. This is a very positive value and a sign of high solvency as it would only need 1.78 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 1.78, ADMA belongs to the best of the industry, outperforming 93.70% of the companies in the same industry.
- A Debt/Equity ratio of 0.16 indicates that ADMA is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.16, ADMA is doing worse than 64.31% of the companies in the same industry.
- Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 20.23 |
ROIC/WACC2.89
WACC8.92%
2.3 Liquidity
- ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of ADMA (7.13) is better than 70.80% of its industry peers.
- ADMA has a Quick Ratio of 3.65. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
- ADMA's Quick ratio of 3.65 is in line compared to the rest of the industry. ADMA outperforms 46.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
- ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.86%, which is quite impressive.
- Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 27.62%.
- Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 70.84% on average per year.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
- Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 33.00% on average per year.
- Based on estimates for the next years, ADMA will show a very strong growth in Revenue. The Revenue will grow by 21.50% on average per year.
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 32.44, which means the current valuation is very expensive for ADMA.
- Based on the Price/Earnings ratio, ADMA is valued cheaper than 93.13% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.18, ADMA is valued at the same level.
- Based on the Price/Forward Earnings ratio of 19.19, the valuation of ADMA can be described as rather expensive.
- Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 94.08% of the companies in the same industry.
- ADMA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.51, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.44 | ||
| Fwd PE | 19.19 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaply inside the industry as 93.32% of the companies are valued more expensively.
- 91.41% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 102.68 | ||
| EV/EBITDA | 23.89 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The decent profitability rating of ADMA may justify a higher PE ratio.
- ADMA's earnings are expected to grow with 33.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.68
PEG (5Y)N/A
EPS Next 2Y35.12%
EPS Next 3Y33.64%
5. Dividend
5.1 Amount
- No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
17.52
+0.02 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners93.5%
Inst Owner Change-3.3%
Ins Owners2.35%
Ins Owner Change-0.33%
Market Cap4.17B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts82.22
Price Target26.18 (49.43%)
Short Float %8.13%
Short Ratio7.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.72%
EPS NY rev (1m)0%
EPS NY rev (3m)3.23%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)1.19%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.44 | ||
| Fwd PE | 19.19 | ||
| P/S | 8.53 | ||
| P/FCF | 102.68 | ||
| P/OCF | 64.18 | ||
| P/B | 9.67 | ||
| P/tB | 9.76 | ||
| EV/EBITDA | 23.89 |
EPS(TTM)0.54
EY3.08%
EPS(NY)0.91
Fwd EY5.21%
FCF(TTM)0.17
FCFY0.97%
OCF(TTM)0.27
OCFY1.56%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.68
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 20.23 |
F-Score7
WACC8.92%
ROIC/WACC2.89
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y36.27%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.